Business Context and Reporting Period
This Form 8-K reports on the results of the 2024 Annual Meeting of Stockholders held by MediciNova, Inc. on June 11, 2024. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market under the symbol MNOV.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
At the record date of April 17, 2024, the Company had 49,046,246 shares of common stock issued and outstanding. A total of 35,566,042 shares were present at the meeting, constituting a quorum. The following matters were submitted to a vote:
- Election of Directors: Two Class II Director nominees were elected to serve until the 2027 Annual Meeting.
- Yuichi Iwaki: 24,341,478 votes For; 7,902,443 votes Against; 886,701 Abstain.
- Kazuko Matsuda: 24,576,097 votes For; 7,667,575 votes Against; 886,949 Abstain.
- Ratification of Auditors: The selection of BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was approved.
- Results: 27,390,814 votes For; 7,519,216 votes Against; 654,012 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the definitive proxy statement filed on April 26, 2024, for detailed background on the director nominees and auditor selection.
- Confirm the total number of shares outstanding (49,046,246) and the quorum threshold met at the Annual Meeting.
- Review the significant number of "Against" votes for both director nominees and the auditor ratification to assess shareholder sentiment.
- Check subsequent filings for the Company's financial performance, as this 8-K contains no financial data.